• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy

by | Feb 4, 2025 | Publications

Anticancer Agents Med Chem. 2025 Jan 30. doi: 10.2174/0118715206350342241224073809. Online ahead of print. ABSTRACT BACKGROUND: Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common,...

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

by | Jan 28, 2025 | Publications

Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025. ABSTRACT BACKGROUND: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the...

Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes

by | Jan 8, 2025 | Publications

Ann Hematol. 2024 Dec;103(12):5849-5859. doi: 10.1007/s00277-024-06129-5. Epub 2024 Dec 7. ABSTRACT Patient-reported outcomes (PROs) are crucial endpoints in multiple myeloma (MM) randomized controlled trials (RCTs), yet there is significant variability in their...

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

by | Jan 7, 2025 | Publications

Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):32-44. doi: 10.1016/j.clml.2024.09.008. Epub 2024 Sep 21. ABSTRACT BACKGROUND: The efficacy of elotuzumab, an anti-SLAMF7 monoclonal antibody, in treating relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed...

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma

by | Jan 7, 2025 | Publications

Front Immunol. 2024 Dec 23;15:1466443. doi: 10.3389/fimmu.2024.1466443. eCollection 2024. ABSTRACT BACKGROUND: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G...

Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review

by | Dec 28, 2024 | Publications

Clin Lymphoma Myeloma Leuk. 2024 Dec 6:S2152-2650(24)02444-3. doi: 10.1016/j.clml.2024.12.006. Online ahead of print. ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of multiple myeloma (MM). Evidence suggested old age,...
« Older Entries
Next Entries »

Recent Content

  • Bortezomib Off-Week Regimen Shows Promise for Reducing Toxicity in Multiple Myeloma
  • Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
  • LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma
  • Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
  • A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
  • How well do different chatbots respond to multiple myeloma treatment guidelines?
  • Emerging Bispecific T-Cell Engagers in Myeloma: Promises and Hurdles
  • Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis
  • Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
  • Understanding the Use of Bispecific Antibodies in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT